Different handling requirements apply to unreconstituted powder versus reconstituted solution
Immunoblotting Cell pellets were washed twice with ice-cold PBS prior to lysis in RIPA buffer (10 mM Tris-Cl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS) supplemented with protease inhibitors Sigma-Aldrich, 11836170001) and phosphatase inhibitors (Roche, 04906837001)
Veronese et al
Several factors may contribute to dizziness in patients taking GLP-1 medications: Hypoglycaemia (low blood glucose) particularly when GLP-1 agonists are used alongside other glucose-lowering medications such as sulphonylureas or insulin Dehydration resulting from reduced fluid intake due to decreased appetite or from gastrointestinal side effects such as nausea, vomiting, or diarrhoea Orthostatic hypotension a drop in blood pressure upon standing, which may occur due to volume depletion or rapid weight loss Reduced caloric intake significant appetite suppression may lead to inadequate nutrition, potentially causing weakness and dizziness The frequency and severity of dizziness vary between individuals and specific GLP-1 products
Effects of four different dietary fibre supplements on weight loss and lipid and glucose serum profiles during energy restriction in patients with traits of metabolic syndrome: a comparative, randomized, placebo-controlled study
Both are exactly the same medication, dosages and results